Fitia vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI nutrition and meal planning app with 10M+ users across Latin America; personalized diet plans and calorie tracking competing with MyFitnessPal for Spanish-speaking health consumers.
About
Fitia is a mobile nutrition and diet app powered by AI-driven meal planning — providing personalized diet plans, automated calorie and macro tracking, food database scanning, and weight loss guidance tailored to each user's goals, body metrics, and food preferences. Founded in 2018 in Lima, Peru by Renato Salas, Fitia is Y Combinator-backed and raised $125,000 from YC alongside Goodwater Capital and HOF Capital, growing to over 10 million users across Latin America and generating $3.5 million in revenue in 2024.\n\nFitia's app builds personalized weekly meal plans based on user-specified goals (weight loss, muscle gain, maintenance), dietary restrictions (vegetarian, gluten-free, lactose intolerance), and food preferences — then automatically calculates the daily calorie and macronutrient targets. Users log meals by searching the app's food database (extensive Latin American and international food coverage), scanning barcodes, or taking photos for AI-powered food recognition. The app's market positioning focuses on making professional-quality nutrition guidance accessible at low cost, serving a demographic that can't afford dietitian consultations.\n\nIn 2025, Fitia competes in the nutrition tracking and diet app market with MyFitnessPal (the dominant calorie tracking app globally), Cronometer, Noom, and regional diet apps for Latin American nutrition and weight management. Latin America represents a large underserved market for digital health apps given the region's rapidly growing smartphone penetration and rising obesity rates driving health consciousness. Fitia's Spanish and Portuguese language capabilities and Latin American food database give it advantages over global competitors in the region. The 2025 strategy focuses on growing the premium subscription conversion rate, expanding to additional Latin American markets, and adding AI-powered coaching features that increase engagement and retention beyond passive calorie tracking.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.